“By dividing and conquering…we’re seeing responses in multiple different subtypes of sarcoma…and moving toward more of an individualized therapy that we try to design for every patient, where we take ...

Over the past four decades, rare disease drug development has evolved from a scientific aspiration into a central pillar of biopharmaceutical innovation. Regulatory reforms, scientific breakthroughs, ...

Bruton tyrosine kinase inhibitors (BTKis) are a cornerstone of chronic lymphocytic leukemia (CLL) therapy, with newer second-generation agents developed to maintain efficacy while improving ...